H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $11

Futu NewsNov 19 16:36 · Ratings

Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges

TipRanksNov 19 11:54

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target

BenzingaNov 18 20:50 · Ratings

Candel Therapeutics Analyst Ratings

BenzingaNov 18 20:49 · Ratings

Promising Potential of Candel Therapeutics' CAN-2409 Drives Buy Rating

TipRanksNov 18 19:26 · Ratings

Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer

BusinesswireNov 18 18:30